This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Blanchard, K. T. Articles by Stoll, R. E. Search for Related Content PubMed PubMed Citation Articles by Blanchard, K. T. Articles by Stoll, R. E. Social Bookmarking                         What's this?

Dermal Carcinogenicity in Transgenic Mice: Relative Responsiveness of Male and Female Hemizygous and Homozygous Tg.AC Mice to 12-O-Tetradecanoylphorbol 13-Acetate (TPA) and Benzene

Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368

D. J. Ball

Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368

H. E. Holden

Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368

S. M. Furst

Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368

J. H. Stoltz

Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368

R. E. Stoll

Department of Toxicology and Safety Assessment, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877-0368

Assessment of the carcinogenic potential of chemical agents continues to rely primarily upon the chronic rodent bioassay, a resource-intensive exercise. Recent advances in transgenic technology offer a potential resource conserving approach to carcinogen detection. Incorporation of oncogenes with known roles in the development of neoplasms into the genomes of laboratory rodents may provide new models with the potential of quickly and accurately separating carcinogenic from noncarcinogenic chemicals. The insertion of the v-Ha-ras oncogene into the genome of FVB/N mice imparts the qualities of genetically initiated skin in the transgenic mouse line designated as Tg.AC. The skin of either hemizygous (animals carrying the transgene on 1 allele) or homozygous (transgene copies on both alleles) Tg.AC mice promptly responds to the application of nongenotoxic carcinogens, such as the classical tumor promoting phorbol esters, with the development of squamous papillomas. Tumor production generally begins after 8-10 applications of 2.5 µg/mouse (3 times/wk) of 12-O-tetradecanoylphorbol 13-acetate (TPA). Maximal tumor response is usually in evidence within 20 wk. If this transgenic mouse line is to be useful in the identification of carcinogenic chemicals, experimental protocols must be systematically optimized. Experiments were conducted to compare the relative responsiveness of male and female hemizygous and homozygous Tg.AC mice to the dermal application of TPA and the known human leukemogen, benzene. Results revealed shipment-related variabilities in the relative responsiveness of hemizygous male and female mice to the application of the proliferative agent. Homozygous mice of both sexes were more reliable and uniform in responsiveness to both TPA and benzene. Therefore, our standard protocol for the conduct of bioassays with the Tg.AC mouse line specifies the use of homozygous males and/or females.

Key Words: Tg.AC mice • transgenic rodent lines • short-term carcinogenicity tests • dermal papillomas • benzene • TPA

Toxicologic Pathology, Vol. 26, No. 4, 541-547 (1998)
DOI: 10.1177/019262339802600410


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. R. Payne and C. J. Kemp p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening Toxicol Pathol, June 1, 2003; 31(4): 355 - 363. [Abstract] [PDF]

				B. Bolon and E. Galbreath Use of Genetically Engineered Mice in Drug Discovery and Development: Wielding Occam's Razor to Prune the Product Portfolio International Journal of Toxicology, January 1, 2002; 21(1): 55 - 64. [Abstract] [PDF]

				F. D. Sistare, K. L. Thompson, R. Honchel, and J. DeGeorge Evaluation of the Tg.AC Transgenic Mouse Assay for Testing the Human Carcinogenic Potential of Pharmaceuticals--Practical Pointers, Mechanistic Clues, and New Questions International Journal of Toxicology, January 1, 2002; 21(1): 65 - 79. [Abstract] [PDF]

				R. E. Stoll, S. M. Furst, J. H. Stoltz, P. D. Lilly, and J. H. Mennear Dermal Carcinogenicity in Transgenic Mice: Effect of Vehicle on Responsiveness of Hemizygous Tg.AC Mice to Phorbol 12-Myristate 13-Acetate (TPA) Toxicol Pathol, August 1, 2001; 29(5): 535 - 540. [Abstract] [PDF]

				R. W. Tennant, S. Stasiewicz, W. C. Eastin, J. H. Mennear, and J. W. Spalding The Tg.AC (v-Ha-ras) Transgenic Mouse: Nature of the Model Toxicol Pathol, January 1, 2001; 29(1_suppl): 51 - 59. [Abstract] [PDF]

				D. Gulezian, D. Jacobson-Kram, C. B. Mccullough, H. Olson, L. Recio, D. Robinson, R. Storer, R. Tennant, J. M. Ward, and D. A. Neumann Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment Toxicol Pathol, May 1, 2000; 28(3): 482 - 499. [Abstract] [PDF]

				K. L. Thompson, B. A. Rosenzweig, and F. D. Sistare An Evaluation of the Hemizygous Transgenic Tg.AC Mouse for Carcinogenicity Testing of Pharmaceuticals. II. A Genotypic Marker that Predicts Tumorigenic Responsiveness Toxicol Pathol, July 1, 1998; 26(4): 548 - 555. [Abstract] [PDF]

				R. R. Maronpot The Potential of Genetically Altered Mice as Animal Models for Carcinogen Identification Toxicol Pathol, July 1, 1998; 26(4): 579 - 581. [PDF]